Corpus Intelligence IC Memo — DOCTORS CENTER HOSPITAL SAN JUAN I 2026-04-26 11:19 UTC
IC Memo — DOCTORS CENTER HOSPITAL SAN JUAN I
Investment Committee Memorandum | PR | 129 beds | Grade C | EBITDA uplift $2.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

DOCTORS CENTER HOSPITAL SAN JUAN I

CCN 400006 | nan, PR | 129 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

DOCTORS CENTER HOSPITAL SAN JUAN I is a 129-bed safety-net/medicaid heavy in nan, PR with $35.9M in net patient revenue and a 2.0% operating margin. The hospital serves a payer mix of 9.2% Medicare, 34.1% Medicaid, and 56.7% commercial.

Thesis: Undervalued. Our ML models identify $2.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.0% to 9.4% (+736bps).

Net Revenue HCRIS$35.9M
Current EBITDA COMPUTED$721K
Operating Margin COMPUTED2.0%
Occupancy HCRIS65.0%
Revenue / Bed COMPUTED$278K
Net-to-Gross HCRIS50.3%
Distress Probability ML55.0%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
39
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of 2.0% places it above the state median. Among 39 size-comparable peers (64-258 beds), the median margin is -9.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (64-258), prioritizing same-state peers. 39 hospitals in the comp set.

HospitalStateBedsRevenueMargin
DOCTORS CENTER HOSPITAL SAN JU (Target)PR129$35.9M2.0%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
ADMIN DE SERVICIOS MEDICOS DE PR65$179.7M-50.0%
HOSPITAL MENONITA CAGUAS INCPR232$114.1M6.8%
DOCTOR CENTER HOSPITAL MANATI PR258$103.4M1.6%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
UNIVERSITY DISCTRICT HOSPITALPR210$97.4M-43.2%
HOSPITAL MENONITA AIBONITOPR129$92.1M-3.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$754K+210bp18mo
Cost to Collect4.5%2.5%$718K+200bp12mo
Denial Rate Reduction12.0%6.5%$711K+198bp12mo
A/R Days Reduction5200.0%3800.0%$437K+122bp9mo
Clean Claim Rate88.0%96.0%$23K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$754K
Cost to Collect
$718K
Denial Rate Reduction
$711K
A/R Days Reduction
$437K
Clean Claim Rate
$23K
Total EBITDA Uplift$2.6M
Current EBITDA$721K
+ RCM Uplift+$2.6M
Pro Forma EBITDA$3.4M
Current Margin2.0%
Pro Forma Margin9.4%
WC Released (1x)$1.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.1M$31.2M28.10x94.9%
Base (11x exit)10.0x11.0x$1.1M$34.6M31.24x99.0%
Bull Case9.0x11.0x$998K$43.7M43.80x113.0%
Bull (12x exit)9.0x12.0x$998K$48.0M48.08x117.0%
Bear Case11.0x10.0x$1.2M$17.6M14.43x70.5%
Bear (11x exit)11.0x11.0x$1.2M$19.8M16.20x74.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (34.1%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 55.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 39 hospitals with 64-258 beds
  • Same-state prioritization (n=40)
  • Comp margins: P25=-20.7% / P50=-9.4% / P75=0.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.